Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.05.2024 | Case report

Adalimumab/methotrexate

Morphea and lack of efficacy

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Venetsanopoulou AI, et al. Development of Morphea Following Treatment with an ADA Biosimilar: A Case Report. Current Rheumatology Reviews 20 : 451-454, No. 4, Jan 2024. Available from: URL: https://dx.doi.org/10.2174/0115733971266803231117072453 [Summarised from an abstract] Venetsanopoulou AI, et al. Development of Morphea Following Treatment with an ADA Biosimilar: A Case Report. Current Rheumatology Reviews 20 : 451-454, No. 4, Jan 2024. Available from: URL: https://dx.doi.org/10.2174/0115733971266803231117072453 [Summarised from an abstract]
Metadaten
Titel
Adalimumab/methotrexate
Morphea and lack of efficacy
Publikationsdatum
01.05.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-58915-9

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Rituximab

Case report

Multiple drugs

Case report

Methotrexate